证券研究报告 | 公司点评 | 医疗器械 华大智造(688114) 报告日期：2025 年 05 月 13 日 装机量大幅提升，替代有望加速 ——华大智造 2024 年及 2025 年一季报点评报告 投资要点 公司 2024 年收入 30.13 亿元，同比增长 3.48%，归母净利润-6.01 亿元；其中 Q4 收入 11.43 亿元，同比增长 61.64%，归母净利润-1.37 亿元，装机量大幅提升拉 动四季度收入超预期。2025 年 Q1 收入 4.55 亿元，同比下降 14.26%，归母净利 润-1.33 亿元。我们认为，随着国产替代的持续加速以及海外拓展，2025 年核心 板块收入增长可期。 华大智造：国产替代加速，海外拓展持续 装机量快速增长，2025 年国产替代有望持续加速 2024 年公司基因测序仪业务实现收入 23.48 亿元，同比增长 2.47%，按照产品类 型看，仪器设备收入 9.60 亿元，同比增长 6.92%，试剂耗材收入 13.73 亿元，同 比增长 1.43%。2024 年公司实现新增销售装机近 1270 台，创历史同期新高，较 去年同期增长约 49%。2025 年 2 月 4 日 ...

证券研究报告 | 公司点评 | 化学制药 复星医药(600196) 报告日期：2025 年 05 月 14 日 创新持续发力，国际化渐入佳境 ——复星医药更新点评 投资要点 ❑ 研发保持高投入，我们看好国际化&创新化持续兑现驱动公司持续增长。 ❑ 业绩：利润快速增长，现金流提升 公司披露 2024 年业绩：2024 年实现营业收入 410.67 亿元(YOY-0.80%)。其中， 创新产品收入稳步增长，核心品种创新型抗 PD-1 单抗斯鲁利单抗注射液（汉斯 状）、CAR-T 细胞治疗产品奕凯达（阿基仑赛注射液）、止吐药物奥康泽（奈妥 匹坦帕洛诺司琼胶囊）以及长效重组人粒细胞集落刺激因子产品珮金（拓培非格 司亭注射液）、心衰和高血压治疗药物一心坦（沙库巴曲缬沙坦钠片）均实现较 快增长。 现金流：有所提升，经营质量较佳。2024 年实现经营现金流 44.77 亿元，同比增 长 31.13%，高于当期经营性利润的增速, 同时通过资产结构优化和严格控制资本 性支出等多项措施，实现自由现金流的提升。 利润端快速增长，费用率下降。2024 年实现归母净利润 27.70 亿元，同比增加 16.08%。扣非净利润 23.14 ...

Investment Rating - The investment rating for the company is "Accumulate" [4] Core Views - The company achieved a revenue of 9.1 billion yuan in Q1 2025, representing a year-on-year increase of 14%, and a net profit attributable to shareholders of 231 million yuan, up 178% [1][2] - The company maintains its positioning in the mass liquor market, focusing on core products and enhancing brand advantages, while optimizing product structure through product renewal and channel development [1][2] - The white liquor business shows stable growth, while the pork business continues to reduce losses [1][2] Financial Summary - Revenue forecast for 2024 is 9.13 billion yuan, with a growth rate of 13.85%, and for 2025, it is projected at 8.60 billion yuan, with a growth rate of 5.78% [3] - The net profit attributable to shareholders is forecasted to be 231 million yuan in 2024, increasing to 293 million yuan in 2025, reflecting a growth rate of 26.89% [3] - Earnings per share are expected to be 0.31 yuan in 2024 and 0.40 yuan in 2025 [3] Product Strategy - The company focuses on core product adjustments to achieve product renewal, leveraging the brand advantage of Niulan Mountain and enhancing the classic Erguotou product series [2] - The company is expected to face revenue growth fluctuations due to the ongoing development of new products and the impact of the pork cycle [2] Market Catalysts - Potential catalysts include better-than-expected sales of new products, market expansion exceeding expectations, and improvements in the pork business profitability [2]

证券研究报告 | 公司点评 | 化学制药 医保放量驱动业绩高增，看好数据催化 ——迪哲医药 2024 年报&2025Q1 业绩点评 投资要点 ❑ 2025Q1 舒沃替尼、戈利昔替尼医保放量驱动业绩高增，商业化管线兑现加速。 舒沃替尼 NDA 获得 FDA 优先审评，DZD8586、DZD6008 即将在 2025 ASCO 公布数据，公司管线差异化优势强，看好商业化加速及更多数据读出催化。 ❑ 业绩：25Q1 医保落地驱动业绩高增 2024 年公司实现销售收入 3.60 亿元，同比增长 294.24%，其中公司 在 2024 年年 末对经销商的库存进行了医保价格的差价补偿，因差额补偿影响 2024 年收入约 5200 万元。2025Q1 公司营业收入达 1.60 亿元，同比增长 96.32%，得益于两款 核心产品舒沃替尼与戈利昔替尼自 2025 年 1 月 1 日起正式执行新版国家医保目 录，驱动业绩高增。 ❑ 催化：看好商业加速和数据读出催化 舒沃替尼： 2025 年 1 月，舒沃替尼用于既往经含铂化疗治疗时或治疗后出现疾 病进展的 EGFR Exon20ins 突变型晚期 NSCLC 的新药上市申请获美国 ...

证券研究报告 | 公司深度 | 电机Ⅱ 微特减速电机隐形冠军，持续拓展下游应用场景 ——江南奕帆深度报告 投资要点 ❑ 深耕微特减速电机领域，持续拓展下游应用场景 公司专注于定制化微特减速电机的研发、制造和销售。公司产品线丰富多样，包 括永磁直流电动机、交直流两用电动机、三相异步电动机和单相电容电动机等， 共计超 3,000 种规格型号。2024 年以来公司业绩持续回暖。2024 年，公司实现营 业收入 2.82 亿元，同比增长 61.69%；归母净利润 0.95 亿元，同比增长 98.51%。 2025Q1，公司实现营业收入 0.55 亿元，同比增长 35.97%；归母净利润 0.17 亿 元，同比增长 28.31%。 ❑ 减速电机千亿赛道，下游应用领域广泛 减速电机是指电机和减速机构的集成体，下游包括输配电、房车、新能源汽车、 太阳能追踪器、太阳能电池板清洗机器人、电动自行车、人形机器人等行业。 2023 年中国市场减速机及配套电机市场规模为 884 亿元，预计 2030 年将达到 1156 亿元，20242030 年的复合增长率 CAGR 为 5.12%。 ❑ 工艺技术及产品质量行业领先，下游客户质优面 ...

证券研究报告 | 浙商早知道 报告日期：2025 年 05 月 14 日 浙商早知道 市场总览 重要推荐 【浙商家电 张云添/芦家宁】TCL 智家（002668）公司点评：冰箱 ODM 出口龙头，有望受益于冰箱出口景气延 续 ——20250512 重要观点 http://www.stocke.com.cn 1/4 请务必阅读正文之后的免责条款部分 2025 年 05 月 14 日 ：王禾 执业证书编号：S1230512110001 ：021-80105901 ：wanghe@stocke.com.cn 大势：5 月 13 日上证指数上涨 0.17%，沪深 300 上涨 0.15%，科创 50 下跌 0.15%，中证 1000 下跌 0.27%，创业 板指下跌 0.12%，恒生指数下跌 1.87%。 行业：5 月 13 日表现最好的行业分别是银行（+1.52%)、美容护理（+1.18%)、医药生物（+0.9%)、交通运输 （+0.72%)、煤炭（+0.62%)，表现最差的行业分别是国防军工（-3.07%)、计算机（-0.8%)、机械设备（- 0.66%)、电子（-0.64%)、通信（-0.61%)。 资金：5 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The report highlights a focus on overseas breakthroughs and anticipates an inflection point in performance for the company [1] - The company is positioned as a leader in intelligent metallurgy equipment, with short-term support from increasing overseas orders and long-term potential from domestic renewal cycles and global trends in self-built steel production capacity [7] Financial Performance Summary 1) Revenue & Profit: - For the full year 2024, revenue is projected at 960 million yuan, down 14.4% year-on-year; net profit attributable to shareholders is expected to be 60 million yuan, down 69.0% year-on-year [6] - In Q4 2024, revenue is expected to be 380 million yuan, up 39.3% year-on-year; net profit attributable to shareholders is projected at 50 million yuan, up 57.8% year-on-year [6] - For Q1 2025, revenue is expected to be 120 million yuan, up 0.8% year-on-year; net profit attributable to shareholders is projected at 10 million yuan, down 10% year-on-year [6] 2) Profitability: - The gross margin for 2024 is expected to be 15.8%, down 12.9 percentage points year-on-year; net profit margin is projected at 5.9%, down 10.4 percentage points year-on-year [6] - In Q1 2025, the gross margin is expected to be 19.8%, down 2.3 percentage points year-on-year, showing some recovery [6] 3) Expense Analysis: - The total expense ratio for 2024 is projected at 6.2%, up 0.3 percentage points year-on-year, with financial expenses increasing due to reduced interest income [6] - In Q1 2025, the total expense ratio is expected to be 11.4%, up 2.7 percentage points year-on-year [6] Business Segmentation - In 2024, revenue from production lines is expected to be 670 million yuan, down 24.5% year-on-year; revenue from spare parts is projected at 280 million yuan, up 26.1% year-on-year [6] - For overseas markets, revenue is expected to be 100 million yuan in 2024, down 73% year-on-year, but with a gross margin of 30.5%, indicating long-term potential [6] Order Outlook - The company secured new orders worth 650 million yuan in 2024, with over 60% from overseas markets, establishing a foundation for performance recovery in 2025 [8] - In Q1 2025, the company signed a contract worth 370 million yuan for a hot-rolled plate production line in Nigeria, indicating ongoing deepening of overseas expansion [8]

Investment Rating - The investment rating for the company is maintained as "Accumulate" [8] Core Views - The company achieved total operating revenue of 1.33 billion yuan in 2024, representing a year-on-year increase of 12.7%. The net profit attributable to shareholders reached 114 million yuan, up 16.2% year-on-year, with a non-recurring net profit of 103 million yuan, increasing by 26.9% [1] - In the first quarter of 2025, the company reported operating revenue of 344 million yuan, a year-on-year growth of 19.8%, and a net profit attributable to shareholders of 32 million yuan, up 31.6% year-on-year [1] - The company is expanding its commercial aerospace business and entering the controllable nuclear fusion sector, with revenue from high-strength high-conductivity copper alloys reaching 590 million yuan, a 10.6% increase year-on-year [2] - The company is investing in R&D for medium and high-voltage contact materials, which contributed to a revenue increase of 19.2% year-on-year, reaching 330 million yuan [3] - Revenue from medical imaging components grew by 24.6% year-on-year to 60.22 million yuan, driven by successful batch supply of CT and DR tube components [4] - The company is gradually entering small-batch supply for optical modules, leveraging the excellent properties of tungsten-copper alloys [5] - Profit forecasts indicate that net profit attributable to shareholders will reach 155 million yuan, 201 million yuan, and 251 million yuan in 2025, 2026, and 2027, respectively, with growth rates of 36.0%, 29.2%, and 25.1% [6] Summary by Sections Financial Performance - In 2024, the company reported total operating revenue of 1.33 billion yuan, a 12.7% increase year-on-year, and a net profit of 114 million yuan, up 16.2% [1] - For Q1 2025, operating revenue was 344 million yuan, a 19.8% increase year-on-year, with a net profit of 32 million yuan, up 31.6% [1] Business Expansion - The company is expanding its commercial aerospace operations and has entered the controllable nuclear fusion market, achieving 590 million yuan in revenue from copper alloys, a 10.6% increase [2] - The medium and high-voltage contact materials segment saw revenue growth of 19.2% year-on-year, reaching 330 million yuan [3] - Medical imaging components revenue increased by 24.6% year-on-year to 60.22 million yuan, supported by successful batch supply [4] - The optical module segment is moving towards small-batch supply, utilizing tungsten-copper alloys [5] Profit Forecasts - The company forecasts net profits of 155 million yuan, 201 million yuan, and 251 million yuan for 2025, 2026, and 2027, with respective growth rates of 36.0%, 29.2%, and 25.1% [6]

证券研究报告 | 公司深度 | 电机Ⅱ 微特减速电机隐形冠军，持续拓展下游应用场景 ——江南奕帆深度报告 投资要点 ❑ 深耕微特减速电机领域，持续拓展下游应用场景 公司专注于定制化微特减速电机的研发、制造和销售。公司产品线丰富多样，包 括永磁直流电动机、交直流两用电动机、三相异步电动机和单相电容电动机等， 共计超 3,000 种规格型号。2024 年以来公司业绩持续回暖。2024 年，公司实现营 业收入 2.82 亿元，同比增长 61.69%；归母净利润 0.95 亿元，同比增长 98.51%。 2025Q1，公司实现营业收入 0.55 亿元，同比增长 35.97%；归母净利润 0.17 亿 元，同比增长 28.31%。 ❑ 减速电机千亿赛道，下游应用领域广泛 减速电机是指电机和减速机构的集成体，下游包括输配电、房车、新能源汽车、 太阳能追踪器、太阳能电池板清洗机器人、电动自行车、人形机器人等行业。 2023 年中国市场减速机及配套电机市场规模为 884 亿元，预计 2030 年将达到 1156 亿元，2024-2030 年的复合增长率 CAGR 为 5.12%。 ❑ 工艺技术及产品质量行业领先，下游客户质优 ...

Investment Rating - The investment rating for the company is "Buy" [3] Core Views - The pre-mixed cocktail segment is under short-term pressure, while the whiskey product line is expected to contribute positively to revenue growth [2][7] - The company launched new whiskey products, including "Bailide" blended whiskey and the "Laizhou" single malt whiskey series, which are anticipated to drive sales [2][7] - The company is focusing on seasonal new product launches to rejuvenate its brand positioning in the pre-mixed cocktail market [7] Revenue and Profitability - For 2024, the company expects revenue of 30.48 billion yuan, a decrease of 6.61% year-on-year, with a net profit of 7.19 billion yuan, down 11.15% [3][7] - The gross margin for 2024 is projected to be 69.67%, with a net margin of 23.50% [2][3] - The company anticipates revenue growth of 9% and 11% for 2025 and 2026, respectively, with net profit growth of 11% and 15% [2][3] Regional Performance - Revenue from different regions for 2024 is as follows: North China 5.56 billion yuan, East China 10.15 billion yuan, South China 9.30 billion yuan, and West China 5.13 billion yuan, with varying year-on-year changes [1][2] Channel Performance - Revenue from distribution and direct sales for 2024 is projected at 21.52 billion yuan and 8.62 billion yuan, respectively, with a year-on-year decrease of 13.30% for distribution and an increase of 19.92% for direct sales [2]